IPF Research Digest, September 27 to October 4, 2026: Twelve New Papers, No New Trials, and Four Computer-Generated Hypotheses From Our Own Software

Where things stand now

IPF remains a serious, progressive lung-scarring disease with no cure available. Two anti-fibrotic pills, pirfenidone and nintedanib, have been approved for years and slow disease progression. A newer approved option, Nerandomilast (Jascayd), received FDA approval in October 2025 and works by calming inflammation and reducing the activation of cells that drive scarring. Inhaled Treprostinil and Admilparant are in late-stage clinical trials and have shown positive Phase III signals, meaning they are promising but not yet fully approved. All of these treatments slow progression. None of them undo scarring that has already formed. Anything beyond that tier is still investigational or experimental.

The best option right now

For people living with IPF right now, the honestly framed picture is this: Nerandomilast (Jascayd) is the most recently FDA-approved option, joining the established anti-fibrotic medicines. It slows how fast the disease progresses but does not reverse damage already done. Inhaled Treprostinil and Admilparant have strong Phase III trial evidence and are moving toward potential approval, but are not yet available as standard prescriptions. Rentosertib, a first-in-class pill targeting a protein called TNIK, has shown early human trial results published in Nature Medicine in 2025 and is still being studied. The right choice for any individual depends entirely on their doctors and personal health situation. No single option is guaranteed to work for everyone.

How close are we to regeneration

True lung regeneration, meaning actually regrowing healthy tissue to replace scar tissue, remains a research goal that does not yet exist as a treatment. The most advanced experimental ideas in this direction include uPAR-CAR-T therapy, which uses engineered immune cells to clear out old, damaging cells from the lung, and a combination approach pairing senolytics (drugs that clear out worn-out cells) with a molecule called RSPO3 that may encourage repair cells to multiply. Both are at the preclinical or concept stage, meaning they have only been tested in lab settings. There were no new regeneration breakthroughs in the data this week.

Study of the week

The editors selected a 2026 paper by Wang, Yin, Niu and colleagues, published in Chinese Journal of Natural Medicines, as the study of the week. The team investigated a plant-derived compound called syringin and asked whether it could slow a specific process in IPF called cellular senescence, which is what happens when lung cells get so damaged they stop working properly but refuse to die and instead release signals that make scarring worse. The researchers found that syringin appeared to interfere with a molecular chain of events involving proteins called ATR, CHK1, and p53, which are part of the system that tells damaged cells to stop dividing. This is early laboratory research. Syringin is not a treatment, and these results would need to go through many more stages, including animal studies and then human trials, before anyone could know whether it is safe or useful for people with IPF.

What changed since last week

Compared to the previous week, no new clinical trials opened and no existing trial statuses changed. The volume of new published papers was notable at twelve, covering a wide range of topics including a UK population study suggesting interstitial lung diseases like IPF are becoming more common in England, a paper exploring the ethical responsibility to tell IPF patients about their elevated lung cancer risk, and laboratory work on proteins such as GPVI in platelets and SLC7A5 that may play roles in driving fibrosis. None of these papers immediately change what treatments are available. They contribute to the scientific understanding that may shape future trials.

What our own software did this week

Our own platform, PF-Atlas, runs a genetic-algorithm solver combined with an AI literature scan. This week, that software, which is our internal model and not an outside research finding, generated four new computer-modelled drug hypotheses. These are: an inhaled formulation of Triiodothyronine (a thyroid hormone) delivered in tiny fat particles called liposomes; a low-dose version of an antibody class called Anti-DLL4, targeting a signalling pathway involved in cell growth; an inhaled RNA-silencing therapy called SPDEF-targeting siRNA, designed to quiet a gene thought to be involved in abnormal cell behaviour in the lung; and an inhaled molecule called a SLIT2-ROBO1 Bispecific Agonist, intended to encourage a type of lung cell called AEC1 to repair damaged tissue. The software also added three items to its broader research pool for further modelling: Chlorogenic Acid (a compound found in plants), a type of mRNA therapy aimed at repairing a specific lung cell type called AEC2, and a Piezo1 inhibitor, which targets a protein that senses physical pressure in cells. Every single one of these is a computer-generated hypothesis. None is a drug, a trial, or a proven treatment. They are the starting points that researchers may choose to investigate further.

Sources this week

• Targeting the Snail1-ATGL-ferroptosis-EMT axis via AKT-GSK3β signaling: Low-dose colchicine attenuates idiopathic pulmonary fibrosis. · European journal of pharmacology 2026 PMID 42785459 on PubMed ↗
• Research on the role and mechanism of SLC7A5 in idiopathic pulmonary fibrosis. · Molecular medicine reports 2026 PMID 42825353 on PubMed ↗
• Pleuroparenchymal fibroelastosis in a UK tertiary ILD centre: determinants of radiological progression and survival. · Respiratory medicine 2026 PMID 42829080 on PubMed ↗
• Management of Pulmonary Hypertension in Interstitial Lung Disease Without Access to Inhaled Treprostinil: A Case Series from a Resource-Limited Setting. · The American journal of the medical sciences 2026 PMID 42826861 on PubMed ↗
• Platelet GPVI drives fibrotic lung remodeling. · Blood advances 2026 PMID 42826704 on PubMed ↗
• The Ethics of Lung Cancer Education for Pulmonary Fibrosis Patients: Addressing Diagnostic Overshadowing and Cancer Risk. · Journal of cancer education : the official journal of the American Association for Cancer Education 2026 PMID 42825871 on PubMed ↗
• End of rarity: the evolving burden of interstitial lung diseases in England - trends from a national population-based cohort study. · Thorax 2026 PMID 42823350 on PubMed ↗
• Evaluation of Pirfenidone as a Novel Radioprotectant for Radiation-induced Intestinal Injury. · Anticancer research 2026 PMID 42823179 on PubMed ↗
• Multi-omics integration reveals the CTSK-cholesterol metabolic axis and the cholesterol-RORA/LDLR paracrine axis in SPP1(+) macrophages as mediators of 6PPD-quinone-induced idiopathic pulmonary fibrosis. · Environmental pollution (Barking, Essex : 1987) 2026 PMID 42822817 on PubMed ↗
• Advances in Prognostic Assessment of Idiopathic Pulmonary Fibrosis: From Clinical-Physiological Parameters and Molecular Biomarkers to Multimodal Models. · Respiratory medicine 2026 PMID 42822813 on PubMed ↗
• Targeting senescence-associated fibrotic signatures identifies syringin as an effective modulator of the ATR/CHK1-p53 axis in idiopathic pulmonary fibrosis. · Chinese journal of natural medicines 2026 PMID 42816034 on PubMed ↗
• Cadherin-11 regulation of type II alveolar epithelial cells during pulmonary fibrosis. · American journal of physiology. Cell physiology 2026 PMID 42750185 on PubMed ↗
• Tarlatamab in Relapsed SCLC With Idiopathic Pulmonary Fibrosis: A Case With Comparative DLL3 Expression Analysis: Case Report. · JTO clinical and research reports 2026 PMID 42733924 on PubMed ↗
• Evaluation of radiological lung pattern and disease progression in patients with asbestosis compared to patients with idiopathic pulmonary fibrosis. · Respiratory medicine 2026 PMID 42660370 on PubMed ↗
• Deciphering the pulmonary fibrosis niche: A single-cell transcriptomic perspective on cellular crosstalk and microenvironment remodeling. · Cytokine & growth factor reviews 2026 PMID 42636652 on PubMed ↗
• Prognostic impact of autoimmune features in interstitial lung disease: a single-center retrospective real-world cohort study. · Clinical rheumatology 2026 PMID 42631904 on PubMed ↗
• Aberrant expression of the PREX2-MAGI2 axis modulates myofibroblast differentiation in pulmonary fibrosis. · American journal of physiology. Lung cellular and molecular physiology 2026 PMID 42631393 on PubMed ↗
• Occupational disease risks in natural resource-based industries among a large cohort of workers in Ontario, Canada. · Work (Reading, Mass.) 2026 PMID 42627631 on PubMed ↗
• MicroRNAs in IPF and lung cancer: convergent and divergent mechanisms: a systematic review. · American journal of physiology. Lung cellular and molecular physiology 2026 PMID 42586526 on PubMed ↗
• GSNOR reprograms nitrosylation to drive endothelial-to-mesenchymal transition and fibrotic vascular remodeling. · Redox biology 2026 PMID 42579926 on PubMed ↗